trending Market Intelligence /marketintelligence/en/news-insights/trending/dIayoX8HDW7xXxNV1dUAIQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

PixarBio drops bid for InVivo Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

PixarBio drops bid for InVivo Therapeutics

PixarBio Corp. dropped its bid for InVivo Therapeutics Holdings Corp., citing "reasons related to management credibility and competence, corporate governance and [intellectual property] control."

In a statement to shareholders, PixarBio said it sees InVivo Therapeutics as "a confused organization" and not worth pursuing at this time.

Earlier in January, InVivo said the nature of PixarBio's offer was "not credible."

Separately, the SEC said it temporarily suspended trading in securities of PixarBio on Jan. 23 due to concerns about possible "manipulative or deceptive activities." The trading suspension will last through Feb. 3.

The SEC also expressed concerns about the accuracy of several PixarBio statements regarding the company's business combinations and current shareholders; the identity and qualifications of key shareholders and employees; and the company's current and prospective development efforts.